A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma

Trial Profile

A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 17 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
    • 22 Nov 2016 Planned End Date changed from 1 Aug 2015 to 1 May 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top